Konjenital Hepatit C İnfeksiyonu

Hepatit B’ye karşı aşılama programlarının başlanmasından sonra Hepatit C (HCV) çocukluk yaş grubu içinde infeksiyon kaynaklı kronik karaciğer hastalığına neden olan başlıca etken olmuştur. HCV açısından kan ürünlerinin rutin taranmaya başlanması ile çocukların bu virus ile infekte olmasına neden olan en sık bulaşma yolunu anneden çocuğa vertikal geçiş oluşturmaya başlamıştır. Anneden çocuğa virus geçişini etkileyen en önemli risk faktörlerini konakçı ve virusun kendisi ile ilgili faktörler oluşturmaktadır. HCV’ye bağlı karaciğer hastalığı yenidoğan dönemi ve çocukluk çağında orta derecede bir hastalık olarak karşımıza çıkmasına rağmen, bu çocukların çoğunda ileriki dönemlerde kronik karaciğer hastalığı gelişebilmektedir. HCV ile enfekte çocukların tedavisi konusunda geniş kapsamlı araştırmalar mevcut değildir. HCV’nin perinatal geçişini engelleyebilecek yeni metodlara ve bu çocukların tedavisinde kullanılabilecek daha etkili ve daha az toksik ilaç tedavilerine gereksinim vardır.

Anahtar Kelimeler:

Viroloji, Terapötikler, Birincil önleme, Hepatit C, Tanı

Congenital Hepatitis C Infection

Since the program of the hepatitis B virus vaccination started, hepatitis C virus (HCV) has become the most significant cause of chronic liver disease of infectious etiology in pediatric age. After the introduction of hepatitis C virus screening of blood units, vertical transmission now seems to be the most common route of hepatitis C virus infection in children. Both viral and host related factors are of importance as risk factors in vertical HCV transmission. Although hepatitis C virus associated liver disease is usually mild throughout infancy and childhood, progression to chronicity occurs in the majority of perinatally infected children. Treatment of HCV infected children has not been studied extensively. More effective and less toxic therapies for young patients with HCV are needed, as are methods to interrupt perinatal transmission of HCV.

Keywords:

Virology, Therapeutics, Primary Prevention, Hepatitis C, Diagnosis,

___

1. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39:5-19.
2. Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16:296- 305.
3. Bradley JS. Hepatitis. In: Remington SS, Klein JO, Wilson CB, Baker CJ, eds. Infectious Diseases of the Fetus and Newborn Infant, 6th ed. Philadelphia, PA, IL: Elsevier Saunders, 2006: 823-43.
4. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30:595-601.5. Darling JM, Wright TL. Immune responses in hepatitis C: is virus or host the problem? Curr Opin Infect Dis 2004; 17:193-8.
6. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127:924-36.
7. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645-55.
8. Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol 2003; 24:456-64.
9. Chang MH. Mother-to-infant transmission of hepatitis C virus. Clin Invest Med 1996; 19:368-72.
10. England K, Pembrey L, Tovo PA, Newell ML. Growth in the first 5 years of life is unaffected in children with perinatally- acquired hepatitis C infection. J Pediatr 2005; 147:227- 32.
11. Pembreya L, Newella ML, Tovob PA. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol 2005; 43:515-25.
12. Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol 2004; 554:211-6.
13. Ruiz-Extremera A, Salmeron J, Torres C, et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000; 19:511-6.
14. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317:437-41.
15. Conte D, Colucci A, Minola E, Fraquelli M, Prati D. Clinical course of pregnant women with chronic hepatitis C virus infection and risk of mother-to-child hepatitis C virus transmission. Dig Liver Dis 2001; 33:366-71.
16. Ferrero S, Lungaro P, Bruzzone BM, Gotta C, Bentivoglio G, Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand 2003; 82:229-34.
17. Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003; 187:345-51.
18. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36:106-13.
19. Giacchino R, Tasso L, Timitilli A, et al. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr 1998; 132:167-9.
20. Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102:355-9.
21. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744-50.
22. Resti M, Bortolotti F, Vajro P, Maggiore G. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis 2003; 35:453-7.
23. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356:904-7.
24. Plunkett BA, Grobman WA. Elective cesarean delivery to prevent perinatal transmission of hepatitis C virus: a cost-effectiveness analysis. Am J Obstet Gynecol 2004; 191:998-1003.
25. Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70:373-7.
26. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-100.
27. Anand BS, Velez M. Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. World J Gastroenterol 2004; 10:2409-11.
28. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36:275-80.
29. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 2002; 24:1515-48.
30. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 33:570-5.
31. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866-70.
32. Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78:305-10.
33. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34:52-8.
34. Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N Engl J Med 2000; 342:290-1.
35. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000; 106: E53.
36. Christensson B, Wiebe T, Akesson A, Widell A. Interferonalpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30:585-6.
37. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42:1010-8.
38. Wirth Ş, Lang T, Gehring S, Gerner P. Recombinant alfainterferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002; 36:1280-4.
39. Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 2004; 26:991- 1025.
40. Schwarz K, Mohan P, Narkewicz M, et al. The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C (abstr 215). Gastroenterology 2003; 124:212.
41. Freitag-Koontz MJ. Prevention of hepatitis B and C transmission during pregnancy and the first year of life. J Perinat Neonatal Nurs 1996; 10:40-55.